Role of oestrogens in vascular physiology and mechanisms of their atheroprotective effect in animal models;Effet des oestrogenes sur la physiologie arterielle et mecanismes de son effet atheroprotecteur chez l'animal

Therapie

Volumn 54, Issue 3, 1999, Pages 339-346

  Arnal, J F ^a   Batkai S ^a   Elhage, R ^a   Darblade, B ^a   Rami, J ^a   Maret, A ^a   Bayard, F ^a  

^a CHU RANGUEIL   (France)

Author keywords

Atheroma; Endothelium; Fatty streak; Nitric oxide; Oestrogens; Vascular physiology

Indexed keywords

ESTROGEN; ESTROGEN RECEPTOR; MEDROXYPROGESTERONE; NITRIC OXIDE; PROGESTERONE; PROTECTIVE AGENT; RECEPTOR SUBTYPE; SUPEROXIDE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTERY WALL; ATHEROSCLEROSIS; BIOAVAILABILITY; BLOOD VESSEL; CONFERENCE PAPER; ESTROGEN THERAPY; GENETIC HETEROGENEITY; LIPID STORAGE; MONKEY; NONHUMAN; PHYSIOLOGY; PRIORITY JOURNAL; ANIMAL; ARTERIOSCLEROSIS; ARTERY; DISEASE MODEL; FEMALE; HUMAN; MALE; PATHOLOGY; PATHOPHYSIOLOGY; REVIEW; VASCULAR SMOOTH MUSCLE;

ANIMALS; ARTERIES; ARTERIOSCLEROSIS; DISEASE MODELS, ANIMAL; ESTROGENS; FEMALE; HUMANS; MALE; MUSCLE, SMOOTH, VASCULAR; RECEPTORS, ESTROGEN;

EID: 0033128021     PISSN: 00405957     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (58)

1. Grodstein F et al. Postmenopausal hormone therapy and morality [see comments]. N Engl J Med 1997; 336: 1769-1775.
2. Hulley S, Grady D. Bush tea: randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. JAMA 1998; 280: 605-613.
3. Bush TL, Barrett-Connor E, Cowan LD et al. Cardiovascular mortality and noncontraceptive estrogen use in women: results from the Lipid Research Clinic's Program Follow-up Study. Circulation 1987; 75: 1102-1109.
4. Renoir JM, Pahl A, Keller U, Baulieu EE. Immunological identification of a 50 kDa Mr FK506-binding immunophilin as a component of the non-DNA binding, hsp90 and hsp70 containing, heterooligomeric form of the chick oviduct progesterone receptor. C R Acad Sci III 1993; 316: 1410-1416.
5. Janknecht R, Hunter T. Transcription. A growing coactivator network [news; comment]. Nature 1996; 383: 22-23.
6. Kuiper GGJM, Enmark E, Pelto-Huikko M et al. Cloning of a novel estrogen receptor expressed in rat prostate and ovary. Proc Natl Acad Sci USA 1996; 93: 5925-5930.
7. Losordo DW, Kearney M, Kim EA et al. Variable expression of the estrogen receptor in normal and atherosclerotic coronary arteries of premenopausal women. Circulation 1994; 89: 1501-1510.
8. Miller VM, Vanhoutte PM. 17b-estradiol augments endothelium-dependent contractions to arachidonic acid in rabbit aorta. Am J Physiol 1990; 258: R1502-R1507.
9. Cheng DY, Gruetter CA. Chronic estrogen alters contractile responsiveness to angiotensin II and norepinephrine in female rat aorta. Eur J Pharmacol 1992; 215: 171-176.
10. Barbacanne MA, Rami J, Michel JB et al. Estradiol decreases endothelium-derived superoxide anion in rat aorta. Effect on NO bioactivity and peroxynitrite production. Cardiovasc Res 1999; 41: 672-682.
11. Gisclard V, Miller VM, Vanhoutte P. Effect of 17b-estradiol on endothelium-dependent responses in the rabbit. J Pharmacol Exp Ther 1988; 244: 19-22.
12. White MM, Zamudio S, Stevens T et al. Estrogens, progesterone, and vascular reactivity: potential cellular mechanisms. Endocrine Rev 1995; 16: 739-751.
13. Arnal JF, Clamens S, Pechet C et al. Ethinylestradiol does not enhance the expression of nitric oxide synthase in bovine aortic endothelial cells but increases the release of bioactive nitric oxide by inhibiting superoxide anion production. Proc Natl Acad Sci USA 1996; 93: 4108-4113.
14. Weiner CP, Martinez E, Zhu LK et al. In vitro release of endothelium-derived relaxing factor by acetylcholine is increased during guinea pig pregnancy. Am J Obstet Gynecol 1989; 161: 1599-1605.
15. Nadaud S, Philippe M, Arnal JF et al. Sustained induction of aortic endothelial nitric oxide synthase expression in vivo in a model of chronic high flow. Circ Res 1996; 79: 857-863.
16. Weiner CP, Lizasoain I, Baylis SA et al. Induction of calcium-dependent nitric oxide synthases by sex hormones. Proc Natl Acad Sci USA 1994; 91: 5212-5216.
17. Xu DL, Martin PY, St John J et al. Upregulation of endothelial and neuronal constitutive nitric oxide synthase in pregnant rats. Am J Physiol 1996; 271: R1739-R1745.
18. Wang X, Barber D, Lewis D et al. Gender and transcritional regulation of NO synthase and ET-1 in porcine aortic endothelial cells. Am J Physiol 1997; 273: H1962-H1967.
19. Lantin-Hermoso R, Rosenfeld C, Yuhanna I et al. Estrogen acutely stimulates NO synthase activity in fetal pulmonary artery endothelium. Am J Physiol 1997; 273: L119-L126.
20. MacRitchie A, Jun S, Chen Z et al. Estrogen upregulates endothelial NO synthase expression in fetal pulmonary endothelium. Circ Res 1997; 81: 355-362.
21. Stary HC, Chandler AB, Glagov S et al. A definition of initial, fatty streak, and intermediate lesions of atherosclerosis: a report from the Committee on Vascular Lesions of the Council on Arteriosclerosis, American Heart Association. Circulation 1994; 89: 2462-2478.
22. Elhage R, Arnal JF, Pierragi M-T et al. Estradiol-17b prevents fatty streak formation in apolipoprotein E-deficient mice. Arterioscl Thromb Vasc Biol 1997; 17: 2679-2684.
23. Hough IL, Zilversmith DB. Effect of 17β-estradiol on aortic cholesterol content and metabolism in cholesterol-fed rabbits. Arteriosclerosis 1986; 6: 57-63.
24. Adams MR, Kaplan JR, Manuck SB et al. Inhibition of coronary artery atherosclerosis by 17β-estradiol in ovariectomized monkeys. Lack of an effect of added progesterone. Arteriosclerosis 1990; 10: 1051-1057.
25. Wagner JD, Clarkson TB, St Clair RW et al. Estrogen and progesterone replacement therapy reduces LDL accumulation in the coronary arteries of surgically postmenopausal cynomolgus monkeys. J Clin Invest 1991; 88: 1995-2002.
26. Hayashi T, Fukuto JM, Ignarro LJ, Chaudhuri G. Basal release of nitric oxide from aortic rings is greater in female rabbits than in male rabbits: implications for atherosclerosis. Proc Natl Acad Sci USA 1992; 89: 11259-11263.
27. Bell DR, Rensberger HJ, Koritnik DR, Koshy A. Estrogen pretreatment directly potentiates endothelium-dependent vasorelaxatioan of porcine coronary arteries. Am J Physiol 1995; 37: H377-H383.
28. Plump AS, Smith JD, Hayek T. Severe hypercholesterolemia and atherosclerosis in apolipoprotein E-deficient mice created by homologous recombination in ES cells. Cell 1997; 71: 343-353.
29. Zhang SH, Reddick RL, Piedrahita JA, Maeda N. Spontaneous hypercholesterolemia and arterial lesions in mice lacking apolipoprotein E. Science 1992; 258: 468-471.
30. Bourassa P-A, Milos PM, Gaynor BJ et al. Estrogen reduces atherosclerotic lesion development in apolipoprotein E-deficient mice. Proc Natl Acad Sci USA 1996; 93: 10022-10027.
31. Holm P, Korsgaard N, Shalmi M et al. Significant reduction of the antiatherogenic effect of estrogen by long-term inhibition of nitric oxide synthesis in cholesterol-clamped rabbits. J Clin Invest 1997; 100: 821-828.
32. Elhage R, Bayard F, Richard V et al. The prevention of fatty streak formation of 17β-estradiol is not mediated by the production of nitric oxide in apolipoprotein E-deficient mice. Circulation 1997; 96: 3048-3052.
33. Liao F, Andalibi A, Qiao J-H et al. Genetic evidence for a common pathway mediating oxidative stress, inflammatory gene induction, and aortic fatty streak formation in mice. J Clin Invest 1994; 94: 877-884.
34. Smith JD, Trogan E, Ginsberg M et al. Decreased atherosclerosis in mice deficient in both macrophage colony-stimulating factor (op) and apolipoprotein E. Proc Natl Acad Sci USA 1995; 92: 8264-8268.
35. Olsen NJ, Kovacs WJ. Gonadal steroids and immunity. Endocrine Rev 1996; 17: 369-384.
36. Deshpande R, Khalili H, Pergolizzi RG et al. Estradiol down-regulates LPS-induced cytokine production and NFkB activation in murine macrophages. Am J Reprod Immunol 1997; 38: 46-54.
37. Frazier-Jessen MR, Kovacs EJ. Estrogen modulation of JE/ monocyte chemoattractant protein-1 mRNA expression in murine macrophages. J Immunol 1995; 154: 1838-1845.
38. Verbeuren TJ, Jordaens FH, Zonnekeyn LL et al. Effect of hypercholesterolemia on vascular reactivity in the rabbit. Circ Res 1986; 58: 552-564.
39. Harrison D. Cellular and molecular mechanisms of endothelial cell dysfunction. J Clin Invest 1997; 100: 2153-2157.
40. Miyagawa K, Rosch J, Stanczyk F, Hermsmeyer K. Medroxyprogesterone interferes with ovarian steroid protection against coronary vasospasm. Nature Med 1997; 3: 324-327.
41. Node K, Kitakaze M, Kosaka H et al. Roles of NO and Ca2+-activated K+ channels in coronary vasodilation induced by 17b-estradiol in ischemic heart failure. FASEB J 1997; 11: 793-799.
42. Rosano GM, Sarrel PM, Poole-Wilson PA, Collins P. Beneficial effect of oestrogen on exercise-induced myocardial ischaemia in women with coronary artery disease [see comments]. Lancet 1993; 342: 133-136.
43. Gilligan DM, Badar DM, Panza JA et al. Effects of estrogen replacement therapy on peripheral vasomotor function in postmenopausal women. Am J Cardiol 1995; 75: 264-268.
44. Chang E, Harley CB. Telomere length and replicative aging in human vascular tissues. Proc Natl Acad Sci USA 1995; 92: 11190-11194.
45. Spyridopoulos I, Sullivan A, Kearney M et al. Estrogen-receptor-mediated inhibition of human endothelial cell apoptosis. Circulation 1997; 95: 1505-1514.
46. Krasinski K, Spyridopoulos I, Asahara T et al. Estradiol accelerates functional endothelial recovery after arterial injury. Circulation 1997; 95: 1768-1772.
47. Iafrati M, Karas R, Aronovitz M et al. Estrogen inhibits the vascular injury response in estrogen receptor a-deficient mice. Nature Med 1997; 3: 545-548.
48. O'Brien JE, Peterson ED, Keeler GP et al. Relation between estrogen replacement therapy and restenosis after percutaneous coronary interventions. J Am Coll Cardiol 1996; 28: 1111-1118.
49. Holm P, Andersen H, Nordestgaard B et al. Effect of oestrogen replacement on development of experimental arteriosclerosis: a study in transplanted and balloon-injured rabbit aortas. Atherosclerosis 1995; 115: 191-200.
50. Holm P, Shalmi M, Korsgaard N et al. A partial estrogen receptor agonist with strong antiatherogenic properties without noticeable effect on reproductive tissue in cholesterol-fed female and male rabbits. Arterioscl Thromb Vasc Biol 1997; 17: 2264-2272.
51. Grese TA et al. Molecular determinants of tissue selectivity in estrogen receptor modulators. Proc Natl Acad Sci USA 1997; 94: 14105-14110.
52. Paech K, Webb P, Kuiper GG et al. Differential ligand activation of estrogen receptors ERalpha and ERbeta at API sites [see comments]. Science 1997; 277: 1508-1510.
53. Jordan VC. Long-term tamoxifen therapy to control or to prevent breast cancer: laboratory concept to clinical trials. Prog Clin Biol Res 1988; 262: 105-123.
54. Grainger DJ, Metcalfe JC. Tamoxifen: teaching an old drug new tricks? Nature Med 1997; 2: 381-385.
55. Black LJ, Sato M, Rowley ER et al. Raloxifene (LY139481 HCI) prevents bone loss and reduces serum cholesterol without causing uterine hypertrophy in ovariectomized rats. J Clin Invest 1994; 93: 63-69.
56. Clarkson T, Anthony M, Jerome CP. Lack of effect of raloxifene on coronary artery atherosclerosis of postmenopausal monkeys [see comments]. J Clin Endocrinol Metab 1998; 83: 721-726.
57. Tham D, Garner C, Haskell W. Potential health benefits of dietary phytoestrogens: a review of the clinical, epidemiological and mechanistic evidence. J Clin Endocrinol Metab 1998; 83: 2223-2235.
58. Anthony M, Clarkson T, Bullock B, Wagner J. Soy protein versus soy phytoestrogens in the prevention of diet-induced coronary artery atherosclerosis of male cynomolgus monkeys. Arterioscler Thromb Vasc Biol 1997; 17: 2524-2531.